Valerie L. Stevenson

Valerie L. Stevenson

Auto-generated profile, based on publicly available information

Valerie L. Stevenson

University College London Hospitals NHS Trust

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Clinical Rehabilitation
Verified
Journal Article
Closed access
PDF file
PTPaul N Taylor
Paul N Taylor
TSTrish Sampson
Trish Sampson
BBBen Beare
Ben Beare
MDMaggie Donavon-Hall
Maggie Donavon-Hall
PTPeter W Thomas
Peter W Thomas
SNSheila Nell
Sheila Nell
Objectives: To assess the feasibility of a multi-site randomised controlled trial to evaluate the effect of functional electrical stimulation on bradykinesia in people with Parkinson’s disease. Design: A two-arm assessor blinded randomised controlled trial with an 18 weeks intervention period and 4 weeks post-intervention follow-up. Setting: Two UK hospitals; a therapy outpatient department in a district general hospital and a specialist neuroscience centre. Participants: A total of 64 participants with idiopathic Parkinson’s disease and slow gait <1.25 ms−1. Interventions: Functional electrical stimulation delivered to the common peroneal nerve while walking in addition to standard care compared with standard care alone. Main measures: Feasibility aims included the determination of sample size, recruitment and retention rates, acceptability of the protocol and confirmation of the primary outcome measure. The outcome measures were 10 m walking speed, Unified Parkinson’s Disease Rating Scale (UPDRS), Mini Balance Evaluation Systems Test, Parkinson’s Disease Questionnaire-39, EuroQol 5-dimension 5-level, New Freezing of Gait questionnaire, Falls Efficacy Score International and falls diary. Participants opinion on the study design and relevance of outcome measures were evaluated using an embedded qualitative study. Results: There was a mean difference between groups of 0.14 ms−1 (CI 0.03, 0.26) at week 18 in favour of the treatment group, which was maintained at week 22, 0.10 ms−1 (CI –0.05, 0.25). There was a mean difference in UPDRS motor examination score of –3.65 (CI –4.35, 0.54) at week 18 which was lost at week 22 –0.91 (CI –2.19, 2.26). Conclusion: The study design and intervention were feasible and supportive for a definitive trial. While both the study protocol and intervention were acceptable, recommendations for modifications are made.

1 September 2008 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
TWThomas E.F. Webb
Thomas E.F. Webb
SPSuvankar Pal
Suvankar Pal
DSDurrenajaf Siddique
Durrenajaf Siddique
DHDominic C. Heaney
Dominic C. Heaney
JLJacqueline M. Linehan
Jacqueline M. Linehan
JCJohn Collinge
John Collinge
Sibling concurrence of pathologically confirmed prion disease has only been reported in association with pathogenic mutation of the prion protein gen

10 April 2019 in Clinical Rehabilitation
Verified
Journal Article
Closed access
PDF file
FJFm Juckes
Fm Juckes
GMG Marceniuk
G Marceniuk
CSC Seary
C Seary
VSVl Stevenson
Vl Stevenson
The objective of this study was to determine the impact on health-related quality of life of functional electrical stimulation used to improve walking in people with multiple sclerosis and to explore cost-effectiveness. A retrospective analysis of patient records was conducted. This study used outpatient therapy service as the study setting. Data from 82 consecutive patients with multiple sclerosis attending for set up with functional electrical stimulation were analysed. Patients were seen at baseline, three and six months for support in use of functional electrical stimulation, and data were collected at baseline and six months. The EQ-5D-5L and walking speed were collected at baseline and six months after using functional electrical stimulation. The Psychosocial Impact of Assistive Device Scale was collected at six months. EQ-5D-3L utilities were derived and cost-effectiveness analysis was completed utilizing a five-year time horizon and methodology published by National Institute for Health and Care Excellence. Significant differences (P < 0.001) were seen in walking speed (baseline 0.670 m/s; with stimulation 0.768 m/s) and maintained over six months (0.772 m/s with stimulation). EQ-5D data significantly improved over six months (baseline 0.486, six months 0.596, P < 0.001) and meaningful mean scores were seen in all aspects of the Psychosocial Impact of Assistive Device Scale. However, there were no correlations between measures. In the cost utility analysis, compared to standard care, functional electrical stimulation was more expensive and more effective with an incremental cost-effectiveness ratio of £6137. Functional electrical stimulation is a cost-effective treatment to improve walking speed and health-related quality of life in people with multiple sclerosis.

17 June 2018 in Clinical Rehabilitation
Verified
Journal Article
Closed access
NHNicola Hare
Nicola Hare
PGPetros Georgopoulos
Petros Georgopoulos
KPKate E Philips
Kate E Philips
JJJoanne E Johnson
Joanne E Johnson
CSCoralie Seary
Coralie Seary
VSValerie L Stevenson
Valerie L Stevenson
Functional electrical stimulation is used to improve walking speed and reduces falls in people with upper motor neurone foot-drop. Following anecdotal observations of changes in bladder symptoms, an observational study was performed to explore this association further. A total of 47 consecutive patients attending for setup with functional electrical stimulation during a six-month period were asked to complete a questionnaire assessing bladder symptoms (ICIQ-OAB (International Consultation on Incontinence Questionnaire Overactive Bladder)) at baseline and three months during routine appointments. In all, 35 (75%) had multiple sclerosis and the other 12 subjects had a total of 9 diagnoses including 3 with stroke. Other conditions included cerebral palsy, motor neurone disease, hereditary spastic paraparesis, meningioma and spinocerebellar ataxias. Improvement in overactive bladder symptoms was not significant in the whole cohort, however, was significant in patients with multiple sclerosis (n = 35; mean change in ICIQ-OAB score 1.0, P = 0.043). Specifically, significant improvements were seen in urgency and urge incontinence in multiple sclerosis patients. There was a significant negative correlation of moderate strength within the multiple sclerosis cohort between baseline walking speed and subsequent change in ICIQ-OAB score (correlation coefficient of r = −0.40, P = 0.046). Thus, greater changes in bladder symptoms were seen with lower baseline walking speeds. The results of this exploratory study suggest that functional electrical stimulation use does improve overactive bladder symptoms in people with multiple sclerosis. Further exploration is needed to study this association and explore whether the mechanism is similar to that of percutaneous tibial nerve stimulation, a recognized treatment for the overactive bladder.

19 October 2021 in JIMD Reports
Verified
Journal Article
Open access
PDF file
WGWilliam Goodison
William Goodison
FBFred Baron
Fred Baron
CSCoralie Seary
Coralie Seary
EMElaine Murphy
Elaine Murphy
RLRobin Lachmann
Robin Lachmann
VSValerie L. Stevenson
Valerie L. Stevenson
Adrenomyeloneuropathy (AMN) is a rare inherited condition where affected individuals develop slowly progressive spastic paraparesis with a gradual decline in walking ability. There is no cure for AMN and treatment focuses on supportive measures and aids. One treatment option is functional electrical stimulation (FES), a treatment, approved by The National Institute for Health and Care Excellence (NICE), for managing foot drop in upper motor neuron disorders. Limited evidence exists for its use in AMN patients. We describe the effects of FES in an individual case and more broadly within a cohort of 21 patients successfully treated with FES. Patients with AMN referred for FES typically report frequent falls (71%) and foot drop (57%) as the most common barriers to walking. When using FES, walking speed at baseline (0.70 m/s [SD = 0.2]) was maintained at the 2‐year review (0.68 m/s [SD = 0.2]) with a persistent orthotic effect (improvement in walking speed when device on vs. off) seen from wearing FES over the same 2‐year period (11%–19%). Patient walking satisfaction (visual analogue scale: 0 – very dissatisfied; 10 – very satisfied) was also greater when comparing no‐FES versus FES over the same period (Year 1: 2.5 vs. 7.7; Year 2: 2.1 vs. 6.1). FES is not effective in all patients. Twelve patients referred found no benefit from the device; although there was no clear evidence, this was related to the degree of AMN associated peripheral neuropathy. However, FES is a safe, cost‐effective treatment option and should be considered, along with assessment in a multidisciplinary clinic, for all AMN patients with walking difficulties.

1 January 2020 in Advances in Clinical Neuroscience & Rehabilitation
Verified
Journal Article
Open access
UHUniversity College London Hospitals
University College London Hospitals
VSValerie Stevenson
Valerie Stevenson
RFRachel Farrell
Rachel Farrell
NSNational Hospital Queen Square
National Hospital Queen Square
GRGita Ramdharry
Gita Ramdharry
SHSarah Holmes
Sarah Holmes
Keywords There is increasing demand on rehabilitation services to manage those with COVID-19 related impairments, and existing patients. Innovative and novel strategies are needed.